Skip to main content

Table 2 Occurrence of acute GVHD

From: Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

Category

Plerixafor group

Control group

p value

n = 30

n = 14

0.90

Acute GVHD

   

 None or grade I

17 (56 %)

54 (57 %)

1.00

 Grade II

8 (26 %)

19 (20 %)

0.60

 Grades III–IV

5 (16 %)

22 (23 %)

0.62

  1. Note: Comparisons among the two groups were performed by the use of the extended Fisher exact test for acute GVHD
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us